This article discusses the potential role of tirofiban as a complementary agent to the newer oral P2Y12 receptor blockers in STEMI patients.
Douglas Jennings, PharmD, FCCP, FAHA
Advertisement
Douglas Jennings, PharmD, FCCP, FAHA, FACC, currently practices as the clinical pharmacy manager in heart transplant and mechanical circulatory support at New York Presbyterian Columbia University Medical Center. He is a past chair of the American College of Clinical Pharmacy (ACCP) Cardiology PRN, and he is a fellow of ACCP, the American Heart Association, and the American College of Cardiology.
Articles by Douglas Jennings, PharmD, FCCP, FAHA
A recently-published study explores the outcomes associated with the combination of DOACs and dual anti platelet therapy.
Advertisement
Latest Updated Articles
- DOACs and DAPT: A Troubling Combination or a Recipe for Success?
Published: December 2nd 2016 | Updated:
- All That Is Old Becomes New Again: New Roles for Old, Antiplatelets in STEMI
Published: August 10th 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
2
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
3
Interim Phase 2 IOV-LUNG-202 Data Show Lifileucel’s Potential Treating Advanced NSCLC
4
Low-Dose Aspirin Linked to Lower Cardiovascular Risk in Type 2 Diabetes
5
